Mirabegron - CAS 223673-61-8
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Adrenergic Receptor
Mirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012. Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity
Publictions citing BOC Sciences Products
  • >> More
YM-178; YM 178; YM178
1. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys
Toshiki Hatanaka & Masashi Ukai & Mai Watanabe. Naunyn-Schmiedeberg's Arch Pharmacol (2013) 386:1001–1008
Mirabegron is the first β3-adrenoceptor agonist with better balance between efficacy and tolerability for the treatment of overactive bladder compared with existing antimuscarinic agents and has been launched in Japan, the USA, and European countries. We previously reported that mirabegron shows relaxant effects on rats and humans bladder smooth muscle strips in vitro (Takasu et al. 2007; Hatanaka et al. 2013a) and ameliorates effects in rat models of overactive bladder (Hatanaka et al. 2013a) and bladder outlet obstruction (Hatanaka et al. 2013b).
2. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men
Hideo Otsuki • Takeo Kosaka • Kenzo Nakamura. Int Urol Nephrol (2013) 45:53–60
Since it was revealed that β3-adrenoceptor acts as a subtype of relaxation of detrusor, β3-adrenoceptor is considered to be one of the targets of OAB pharmacotherapy. Another action of β3-adrenoceptor agonist is to enhance the storage function of the bladder with less effect on detrusor pressure during micturition and post-void residual urine volume. As a result, mirabegron improves urinary urgency, frequency, and urgency incontinence. The usefulness of β3-adrenoceptor agonist was verified both in vitro and in vivo. Mirabegron appeared on the Japanese market in September 2011, and it provides a new treatment option for OAB.
3. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials
Yuanshan Cui • Huantao Zong. Int Urol Nephrol (2014) 46:275–284
Mirabegron, a selective β3-adrenoceptor (AR) agonist, is a first in class drug for the treatment of OAB. β3-ARs account for more than 95 % of all b-AR mRNA in the human bladder and are thought to be the main β-ARs mediating human detrusor relaxation. β3-ARs have been found to be highly and preferentially expressed on urinary bladder tissues, including the urothelium, interstitial cells and detrusor smooth muscle, suggesting mirabegron as a new effective and well-tolerated class of drug for patient with OAB symptoms.
4. Mirabegron for Male Lower Urinary Tract Symptoms
Oscar Suarez & David Osborn & Melissa Kaufman. Curr Urol Rep (2013) 14:580–584
Nitti et al enrolled 1,329 patients (24 % male) with OAB and randomly assigned them to one of three treatment arms: placebo, mirabegron 50 mg and mirabegron 100 mg for 12 weeks [19•]. Mirabegron was well tolerated and showed statistically significant reductions in the number of incontinence episodes and in the number of micturitions per 24-h period compared with placebo. Khullar et al carried out a similar randomized European-Australian multicenter trial in which they enrolled 1,978 patients (28 % male) with OAB [20]. In this study, after a 2-week placebo run-in period, patients were randomized to receive placebo, mirabegron 50 mg, mirabegron 100 mg or the active control, tolterodine ER, for 12 weeks. When compared to placebo, mirabegron demonstrated a statistically significant decrease from baseline in mean number of micturitions and mean number of incontinence episodes per 24-h period. Both doses of mirabegron were effective in improving co-primary efficacy endpoints versus placebo.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Adrenergic Receptor Products

CAS 329-65-7 DL-Adrenaline

(CAS: 329-65-7)

DL-Adrenaline is a hormone and a neurotransmitter secreted by the medulla of the adrenal glands.

CAS 152520-56-4 Nebivolol

(CAS: 152520-56-4)

Nebivolol selectively inhibits β1-adrenoceptor with IC50 of 0.8 nM.

(CAS: 65321-41-7)

MK-761 has beta adrenoceptor antagonist and vasodilating properties in a single molecule. It has beta adrenoceptor blocking activity in the isolated cat heart p...

CAS 65576-45-6 Asenapine

(CAS: 65576-45-6)

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug by combining serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related ...

CAS 23256-50-0 Guanabenz Acetate

Guanabenz Acetate
(CAS: 23256-50-0)

Guanabenz Acetate is an selective agonist of α2a-adrenergic receptor, α2b-adrenergic receptor and α2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respe...

CAS 84638-81-3 ZK-90055 hydrochloride

ZK-90055 hydrochloride
(CAS: 84638-81-3)

ZK-90055, a β‐Adrenoceptor agonist, is a B-2 bronchodilator drug.

CP 59430
(CAS: 86329-06-8)

CP 59430 is an azide analog of prazosin. It is a selective alpha 1-adrenergic receptor antagonist.

CAS 133242-30-5 Landiolol

(CAS: 133242-30-5)

Landiolol is an ultra-short-acting Beta 1 adrenergic receptor antagonist using for managing supraventricular tachyarrhythmias in sepsis. It is also used as an a...

CAS 77883-43-3 Doxazosin Mesylate

Doxazosin Mesylate
(CAS: 77883-43-3)

Doxazosin mesylate is an α1-selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia.

CAS 65023-16-7 Bometolol Hydrochloride

Bometolol Hydrochloride
(CAS: 65023-16-7)

Bometolol is a beta-adrenergic blocking drug.

CAS 138908-40-4 CL-316243 sodium

CL-316243 sodium
(CAS: 138908-40-4)

CL-316243 is a highly selective β3-adrenoceptor agonist with EC50 value of 3 nM; > 10000-fold selective over β1 and β2 receptors. CL-316243 can restore the expr...

(CAS: 451470-34-1)

Solabegron is a selective β3-adrenergic receptor agonist used for the treatment of irritable bowel syndrome.


(RS)-Butyryltimolol is the racemate of Butyryltimolol which is the butyryl ester of Timolol. Timolol, in the non-selective β blocker family of medication, has b...

CAS 13523-86-9 Pindolol

(CAS: 13523-86-9)

Pindolol, an Indole derivative, could be used in the treatment of hypertension and arrhythmia for acting as a 5-HT1A/1B receptor antagonist. IC50: 33nM(Ki).

CAS 5704-60-9 Nifenalol HCl

Nifenalol HCl
(CAS: 5704-60-9)

Nifenalol, also known as INPEA, is a novel antagonist of β-adrenoceptors.

CAS 106133-20-4 Tamsulosin

(CAS: 106133-20-4)

Tamsulosin could block on the sympathetic α1 receptor, especially selectively bind to the α1A receptor and has been found to be effective in the treatment of be...

CAS 65652-44-0 Pirbuterol acetate

Pirbuterol acetate
(CAS: 65652-44-0)

Pirbuterol acetate is a short-acting β2 adrenoreceptor agonist. It has bronchodilating action and is used as a bronchodilator. It is also used in the treatment ...

CAS 4205-91-8 Clonidine Hydrochloride

Clonidine Hydrochloride
(CAS: 4205-91-8)

Clonidine HCl is a direct-acting α2 adrenergic agonist with an ED50 of 0.02±0.01 mg/kg.

CAS 104075-48-1 Atipamezole hydroChloride

Atipamezole hydroChloride
(CAS: 104075-48-1)

The hydrochloride salt form of atipamezole that is an alpha2-adrenoceptor blocker which could be used for animals to recover from the anesthesia by lowering blo...

CAS 5985-28-4 Synephrine Hydrochloride

Synephrine Hydrochloride
(CAS: 5985-28-4)

SynephrineHCl (Oxedrine, p-Synephrine) is a sympathomimetic α-adrenergic receptor (AR) agonist.

Chemical Structure

CAS 223673-61-8 Mirabegron

Quick Inquiry

Verification code

Featured Items